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Abstract 
Pathogenic strains of Acanthamoeba cause keratitis (AK), granulomatous 
amoebic encephalitis (GAE), amoebic pneumonitis (AP), and skin infection 
in human and animals. The treatment of an Acanthamoeba infection is inva-
riably very difficult and not always effective, and compounds that are amebi-
cidic or amebistatic are frequently toxic and/or irritating for humans. Squa-
ramides and polyamine derivatives have been demonstrated to have antitu-
mor and antiprotozoal activity. The aim of this study was to investigate the 
activity of 5 squaramides and 5 acyclic polyamines against trophozoites and 
cysts of A. castellanii Neff. Amoebicidal activity against the trophozoites and 
cytotoxicity against Vero cells were evaluated with a colorimetric assay, using 
Alamar Blue®, and chlorhexidine digluconate was assayed as the reference 
drug. The squaramides 3 and 5 and the acyclic polyamine 6 appeared to be 
the most active against the trophozoites and their cytotoxicity was low, 
showing selectivity indexes of 28.3, 26, and 25.7, respectively, similar to the 
control drug, chlorhexidine digluconate (27.6). But only the squaramide 3 
showed complete cysticidal activity at the concentrations of 100 and 200 µM, 
as the chlorhexidine digluconate. Further studies of the mechanism of action 
and in vivo assays are needed, but squaramide 3 could be used for developing 
novel therapeutic approaches against Acanthamoeba infections. 
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1. Introduction 
Acanthamoeba is a free-living opportunistic protozoan parasite that is distri-
buted in diverse environments including air, soil, freshwater, seawater, tap wa-
ter, bottled mineral water, laboratory distilled water wash bottles, chlorinated 
swimming pools, and sewage. In addition, Acanthamoeba is known to among 
the most ubiquitous organisms that can be isolated from fish, reptiles, birds, and 
mammals [1] [2] [3] [4]. In fact, over 80% of immunocompetent individuals 
bear serum antibodies against Acanthamoeba antigens [5], clearly suggesting our 
common exposure to this parasite. Some Acanthamoeba species, such as Acan-
thamoeba castellanii, can cause amoebic keratitis (AK) in immunocompetent 
and immunocompromised individuals [6] [7], which is often associated with 
contact-lens wearers, as first reported by Naginton et al. [8]. On the other hand, 
immunocompromised individuals, including patients with AIDS, diabetes, lupus 
erythematosus or chemotherapy disorders, can develop granulomatous amoebic 
encephalitis (GAE) [9] [10]. However, this type of encephalitis is rarely observed 
in healthy people [11]. Amoebic pneumonitis (AP) as well as chronic lung and 
skin infection can be caused by Acanthamoeba, too. In addition, Acanthamoeba 
can serve as reservoirs for other pathogenic bacteria that are able to divide or 
simply survive within the cysts, such as Pseudomonas, Legionella, Mycobacte-
rium, and Francisella tularensis [12] [13] [14]. 
Today, the therapy of these diseases is still problematic due to the lack of suf-
ficiently effective drugs, resistance of the amoebas, variable efficacy between 
strains or species, and toxicity. 
Therefore, there is a clear need for new anti-Acanthamoeba drugs. In recent 
years, many new treatments, natural and synthetic, have been tested with differ-
ent degrees of success [15]-[24]. 
In this study, we have evaluated the effectiveness of several squaramides and 
acyclic polyamine compounds of new synthesis against trophozoites and cysts of 
Acanthamoeba castellanii Neff strain. Squaramide-based compounds have been 
demonstrated to be therapeutic, and we have described some series of oligomeric 
cyclosquaramides as kinase inhibitors with antitumor activity [25]. The antipa-
rasitic activity of squaramides has been demonstrated, also, some showing anti-
malarial [26] and others antichagasic activity [27]. On the other hand, several 
macrocyclic scorpiand-like polyamines have proved effective against both the 
acute and chronic phases of Chagas disease [28]. 
2. Materials and Methods 
2.1. Culture of Acanthamoeba castellanii Trophozoites and  
Encystment 
Acanthamoeba castellanii Neff (ATCC 30010), obtained from The Center of 
Scientific Instrumentation of the University of Granada, was used in this study.  
Trophozoites were axenically cultured in Falcon Flasks with Casitone Glucose 
Vitamins medium (CGV) supplemented with 10% inactivated fetal calf serum, 
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[29], at 28˚C. 
Cyst forms were obtained as previously described, [30]. Briefly, Acanthamoe-
ba trophozoites medium CGV was removed and 8% glucose in Roswell Park 
Memorial Institute medium (RPMI) 1640 was added. Amoebas were incubated 
at 30˚C for up to 48 h, followed by the addition of Sodium Dodecyl Sulfate (SDS) 
(0.5% final conc.). The trophozoites are SDS-sensitive and are immediately lysed 
upon addition of SDS, while cysts are SDS-resistant and remain intact [30]. 
2.2. Drugs Tested 
The compounds tested were the squaramides and acyclic polyamines shown in 
Table 1. Squaramides 1 to 5 have a common side chain consisting of a N-(3- 
(dimetylaminopropyl)-N-methyl residue. This residue has proven critical for the 
design of squaramide-based antichagasic agents [27]. The second arm of the 
squaramide consisted of aliphatic chains with increasing lengths aimed at im-
proving the lipophilicity of the squaramides. The amines tested are ethylenedia-
mine derivatives with amine group mono- or dimethylated amine and the other 
one functionalized with a methyl pyridine substituent. 
For amoebicidal assays, squaramides and acyclic polyamines were prepared at 
different concentrations of 400, 200, 100, 50, 25, and 10 µM in CGV medium 
with 10% inactivated fetal bovine serum. The drugs were prepared at 200, 100, 
50, and 10 µM concentrations in RPMI medium with 8% glucose for the studies 
of cysticidal activity. For cytotoxicity test on Vero cells the drugs were prepared 
at 800, 400, 200, 100, and 50 µM concentrations in RPMI with 10% inactivated 
fetal bovine serum. 
Chlorhexidine digluconate (Sigma, Aldrich Ltd) was used as the control drug 
against A. castellanii and was prepared in the same way as the squaramides and 
acyclic polyamines. 
The solutions of the compounds were stored at −20˚C [27] [28]. These squa-
ramides and acyclic polyamines are stable in this medium and can be stored 
without decomposition for long periods of time. 
2.3. In Vitro Amoebicidal Assays 
AlamarBlue Assay Reagent® was used in order to determine the A. castellanii an-
ti-trophozoite activity of the squaramides and acyclic polyamines as previously 
described [15] [31] with some modifications.Assays were conducted using a 
96-well microtiter plate (Sigma, Aldrich). Briefly, 1 × 104 trophozoites, in 100 µl 
of CGV medium with 10% inactivated fetal bovine serum, were seeded in the 
microtiter plates and were allowed to adhere for incubation 1 h at 28˚C. 
After that, 100 µl of the solutions of the squaramides or acyclic polyamines 
prepared at 400, 200, 100, 50, 25, and 10 µM were added to each well. Alamar-
Blue Assay Reagent® (Thermo Fisher Scientific) was placed into each well at 10% 
of the final volume, 20 µl. Test plates were incubated for 120 h at 28˚C in com-
plete darkness to avoid the oxidation of the resazurin with the light. The plates  
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Table 1. Squaramides and Acyclic Polyamines tested against Acanthamoeba castellanii. 
Chemical structure Chemical name 
Squaramides 
1  
3-((3-(dimethylamino)propyl)(methyl)amino)-4-(hexylamino)cyclobut-3-ene-1,2-dione 
2  
3-((3-(dimethylamino)propyl)(methyl)amino)-4-(octylamino)cyclobut-3-ene-1,2-dione 
3  
3-((3-(dimethylamino)propyl)(methyl)amino)-4-(dodecylamino)cyclobut-3-ene-1,2-dione 
4  
3-((3-(dimethylamino)propyl)(methyl)amino)-4-(hexadecylamino)cyclobut-3-ene-1,2-dione 
5  
3-((3-(dimethylamino)propyl)(methyl)amino)-4-(dodecyloxy)cyclobut-3-ene-1,2-dione 
Acyclic Polyamines 
6  
1-(2-piridil)-5-metil-2,5-diazahexano 
7  
1-(3-piridil)-5-metil-2,5-diazahexano 
8  
1-(2-piridil)-2,5-diazahexano 
9  
1-(3-piridil)-2,5-diazahexano 
10  
1-(4-piridil)-2,5-diazahexano 
 
were subsequently analyzed using a test wavelength of 570 nm and a reference 
wavelength of 630 nm with a microplate absorbance reader (SunriseTM, Tecan). 
Chlorhexidine digluconate (Sigma, Aldrich Ltd) was used as reference drug 
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against A. castellanii trophozoites. This control drugs and other controls only 
with trophozoites, without drugs, were tested in the same way. 
All the experiments were performed in quadruplicate and the concentration 
required to give 50% inhibition (IC50) was calculated by linear regression analy-
sis from Kc values at the concentrations used, (5, 12.5, 25, 50, 100, and 200 µM). 
Selective indexes, (IC50 Vero cells toxicity/IC50 activity on trophozoites forms of 
the parasite), were also calculated. 
2.4. Cysticidal Activity Assays 
Acanthamoeba castellanii cysts were obtained according to Cordingley et al. 
[30]. Cysts were washed twice with RPMI medium. Afterwards, 1 × 104 cyst were 
added to each well of a microtiter plate in 200 µl of the RPMI with 8% glucose 
and the compounds at 200, 100, 50, and 10 µM. In the same way was tested the 
control drug, chlorhexidine digluconate. 
The microtiter plate was incubated for 120 h at 28˚C. Finally, cysts were 
slightly washed and fresh CGV medium with 10% inactivated fetal bovine serum 
was added to each well, the microtiter plate was incubated at 28˚C, and the 
number of cysts and trophozoites were counted using a Neubauer chamber at 
different times of 24, 48, 72, 120, and 192 h. The presence of trophozoites was 
considered as indication of cyst viability. 
Controls only with cysts, without drugs, were tested in the same way.  
All the experiments were made in quadruplicate 
2.5. Cytotoxicity Test on Vero Cells 
The cytotoxicity induced by each compound was tested with Vero cells (ATCC 
CCL-81) growing in RPMI (Gibco) supplemented with 10% inactivated fetal bo-
vine serum in a humidified 95% air and 5% CO2 atmosphere at 37˚C. Vero cells, 
104 in 100 µl of medium, were added to each well of a microtiter plate and incu-
bated for 24 h at 37˚C in a humid atmosphere enriched with 5% CO2. Next, 100 µl 
of the drug prepared at 800, 400, 200, 100, and 50 µM were added to each well. 
AlamarBlue Assay Reagent® (Thermo Fisher Scientific) was placed into each well 
at 10% of the final volume, 20 µl. Test plates were incubated for 120 h at 37˚C 
and were subsequently analyzed using a test wavelength of 570 nm and a refer-
ence wavelength of 630 nm with a microplate absorbance reader (SunriseTM, Te-
can). 
Vero cells were treated with chlorhexidine digluconate in the same way and a 
control with only Vero cells without treatment were done. 
All the experiments were conducted in quadruplicate and the concentration 
required to give 50% inhibition (IC50) was calculated by linear regression analy-
sis from Kc values at the concentrations used (400, 200, 100, 50 and 25 µM).  
3. Results and Discussion 
Amoebic keratitis (AK) is normally treated with a combination of a diamidine 
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(hexamidine or propamidine isothionate) and a biguanide (chlorhexidine or po-
lyhexamethylene biguanide) [32] [33]. However, drug resistance against AK 
treatment has been demonstrated [4] [32] [34] [35] [36] and at present, there is 
no completely effective treatment for granulomatous amoebic encephalitis GAE 
[20]. 
For a better treatment against Acanthamoeba, we assayed two groups of 
compounds: squaramides and acyclic polyamines (Table 1). Antiparasitic activ-
ity (antimalarial and anti-Chagas) has been demonstrated for some of them [26] 
[27] [28]. Some aminosquaramide compounds induced changes in the T. cruzi 
glycolysis cycle and caused cytoplasmic and mitochondrial alterations [27] [28]. 
We assayed the amoebicidal and cysticidal activity of 5 squaramides and 5 
acyclic polyamines against A. castellanii Neff vs. the reference drug, chlorhex-
idine digluconate, a standard antiseptic used treating Acanthamoeba keratitis 
with demonstrated cysticidal activity [9] [34]. 
The cytotoxic activity of the compounds was assayed against mammalian Ve-
ro cells and the selective index (IC50 Vero cells toxicity/IC50 activity on tropho-
zoites forms of the parasite) was calculated for each drugs. 
AlamarBlue Assay Reagent® was used to determine the anti-trophozoite, of A. 
castellanii, and cytotoxic activity. This technique was used because it is easy, 
sensitive and cheap. Resazurin, which is the active ingredient of AlamarBlue® 
reagent, is a non-toxic, cell-permeable compound that is blue colored and vir-
tually non-fluorescent. Upon entering cells, resazurin is reduced to resorufin, a 
compound that is red in color and highly fluorescent. Viable cells continuously 
convert resazurin to resorufin, intensifying the overall fluorescence and color of 
the media surrounding cells. 
The in vitro trophocidal activity, cytotoxicity, and selectivity indexes are 
summarised in Table 2. The analysis of these results reveals that two squara-
mides, 3 and 5, and two acyclic polyamines, 6 and 7, were the most effective 
against trophozoites of A. castellanii. Squaramide 3 gave the lowest IC50 value, 
3.5 ± 0.5 µM vs. 5.3 ± 3.1 µM of the chlorhexidine digluconate, and its selectivity 
index was higher than for the control drug (28.3 vs. 27.64). Squaramide 5 with 
IC50 of 11.4 ± 1.2 and selectivity index of 26 showed lower trophocidal activity 
than that of squaramide 3 and the control drug but was less cytotoxic. Both squ-
aramides feature similar structures but different substitution patterns of the 
cyclobutendione moiety. Squaramide 3 is a N, N-bisubstituted compound while 
squaramide 5 is a N,O squaramide (sometimes referred as squaramide-esters). 
Thus, the substitution of a NH group by O markedly disturbs the trophocidal 
activity but, at the same time, drastically reduces the cytotoxicity of 5. It is worth 
noting the parallelism between squaramide 3 and 5 and miltefosine, MF, (Figure 
1). Miltefosine is a medication used mainly to treat leishmaniasis [37] and 
free-living amoeba infections such as granulomatous amoebic encephalitis 
caused by Acanthamoeba spp. and Balamuthia mandrillaris and primary amoe-
bic meningoencephalitis caused by Naegleria fowleri [38] [39]. In 2013, two 
children survived and recovered from primary amoebic meningoencephalitis  
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Table 2. In vitro activity, toxicity and selectivity index for squaramides and acyclic po-
lyamines derivatives on trophozoites of Acanthamoeba castellanii. 
Compounds Activity IC50 (µM)a 
Toxicity IC50 
Vero cells (µM)b Selectivity index
c 
Chlorhexidine  
digluconate 5.33 ± 3 147.34 ± 1.7 27.6 
1 91.3 ± 4.1 100.2 ± 2.3 1.09 
2 134.3 ± 1.2 156.7 ± 3.5 1.16 
3 3.5 ± 0.5 99.3 ± 1.2 28.3 
4 343.5 ± 4.6 100.5 ± 6.9 0.3 
5 11.4 ± 1.2 296.3 ± 3.6 26 
6 26.7 ± 0.5 685.4 ± 8.6 25.7 
7 36.9 ± 0.7 327.53 ± 3.6 8.87 
8 783.9 ± 1.2 256.4 ± 38.2 0.33 
9 186.3 ± 0.8 846.8 ± 22.9 4.54 
10 278 ± 0.4 321.9 ± 40.9 1.15 
 
 
Figure 1. Molecular structures of squaramides 3 and 5 compared to that of 
the miltefosine (MF). 
 
after treatment with miltefosine [39] [40]. In 2016, after treatment that included 
miltefosine, another child became the fourth person in the United States to sur-
vive Naegleria fowleri infection [41]. 
In the neutral or slightly acidic intracellular cytoplasmatic environment of the 
parasite, squaramide 3 and 5 are heavily protonated at the dimethyl amino 
group. On the other hand, the squaramide moiety is known to act as a successful 
masked phosphate group in bioisosteric replacement [42] [43]. 
Although all the acyclic polyamines (6-10) were less effective against the tro-
phozoites than the squaramides, their cytotoxicity against Vero cells was very 
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low, reaching a selectivity index of 25.7 for polyamine 6. While polyamines 6 
and 7 are isomers, differing only in the disposition of the nitrogen of the pyri-
dine ring, their differences in amoebicidal activity and cytotoxicity was remarka-
ble, with polyamine 7 showing a selective index of only 8.87. Notably, isomeric 
polyamines 8-10, which differ from 6-7 in the presence of only one methyl group 
instead of two at one of their ends, registered much lower amoebicidal activity, 
(Table 1). 
The effect of the drugs against the trophozoites was observed by inverted mi-
croscopy. Figure 2 shows the appearance of the trophozoites at the lowest con-
centration tested, 5 µM, after 120 h of treatment with chlorhexidine digluconate 
(Figure 2(b)) and with the most effective compounds: 3 (Figure 2(c)), 5 (Figure 
2(d)), and 6 (Figure 2(e)). It was observed that the alterations were dose de-
pendent, but at the lower concentration (5 µM) many trophozoites were de-
tached and dead, appearing agglutinated and floating in the supernatant, espe-
cially with chlorhexidine digluconate (Figure 2(b)) and compound 3 (Figure 
2(c)). Treated trophozoites showed structural alterations such as reduction in size, 
loss of acanthopodia and roundness vs. the control trophozoites (Figure 2(a)). 
Trophozoites treated with the highest concentration of compounds (200 µM) 
during 120 h are showed in Figures 2(f)-(i). They were rounded, agglutinated, 
without internal content, dead and many cells debris from the destruction of the 
trophozoites appeared floating in the supernatant Figures 2(f)-(h). Figures 2(i) 
shows trophozoites treated with polyamine 6 with similar appearance to that 
treated with 5 µM concentration. 
After the study of the amoebicidal and cytoxic activity of the drugs, squara-
mides 3 and 5 and polyamine 6 were selected to be tested against A. castellanii 
cysts, which are less susceptible to the treatments than are trophozoites. Al-
though in many recent publications on chemotherapy against Acanthamoeba, 
[15] [17] [18] [22] [24] [44], only the amoebicidal activity of the different prod-
ucts is assayed, it has become evident that it is necessary to know the cysticidal 
activity because trophozoites and cysts are present in the eyes, lungs, brain, and 
skin of the patients, and a good treatment against the trophozoite is not always 
effective against cysts, which are more resistant. Figure 3 shows the cysticidal 
activity of the chlorhexidine digluconate (Figure 3(a)) and compounds 3, 5 and 
6 (Figures 3(b)-(d), respectively) versus a control of cysts without treatment. 
The results showed that no cysts reverted to trophozoites with chlorhexidine 
digluconate and compound 3, (Figure 3(a) and Figure 3(b)), at 100 and 200 µM 
during of 192 h that the study lasted, and therefore they were presumed to be 
non-viable. When cysts were treated with 50 µM of these drugs, very few tro-
phozoites (no more than 9%) could be seen. The cysts treated with compound 5 
and 6 reverted with time to trophozoites at the concentrations assayed (Figure 
3(a) and Figure 3(d)). 
Chlorhexidine digluconate is used at 0.02% concentration in the initial thera-
py of Acanthamoeba keratitis. It acts by damaging the membrane of the  
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Figure 2. a) Trophozoites control of Acanthamoeba castellanii Neff. (b)-(e) Trophozoites 
treated with chlorhexidine digluconate (b) and compounds 3 (c), 5 (d), 6 (e) at concen-
tration 5 µM during 120 h. They appeared detached, rounded, agglutinated and floating 
in the supernatant. (f)-(i) Trophozoites treated with chorhexidine digluconate (f) and 
compounds 3 (g), 5 (h), 6 (i) at concentration 200 µM during 120 h. Trophozoites in (f), 
(g) and (h) were dead and cell debris appeared floating in the supernatant. ×400. Scale bar 
= 10 µm. 
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Figure 3. Percentage of cysts when they were treated with: (a) Chlorhexidine digluconate, (b) Squaramide 3, (c) Squaramide 5 and 
(d) Polyamine 6. No cysts reverted to trophozoites with chlorhexidine digluconate (a) and compound 3 (b) at 100 and 200 µM 
during of 192 h. 
 
amoebas, with irreversible loss of calcium and cell electrolytes from the cytop-
lasm, causing cell lysis and death [32]. However, it is difficult to believe that a 
chemical destroying the membrane of the amoeba would not at the same time 
affect the plasma membranes of the ocular cells, and it has been demonstrated 
that with continued medical treatment, the iris and lens cells die, and cataracts 
develop [45]. Also, the cysticidal activity of chlorhexidine digluconate at 0.02% is 
only of the 80% [44]. In this study, cysticidal activity of chlorhexidine digluco-
nate and squaramide 3 was similar, but squaramide 3 was more effective against 
the trophozoites and thus served as an alternative in the treatment of Acantha-
M. J. Rosales et al. 
 
 
DOI: 10.4236/jbm.2018.68001 11 Journal of Biosciences and Medicines 
 
moeba infections, (AK, GAE, EP), according to in vivo tests. However, chlor-
hexidine digluconate has shown poor corneal penetration into the anterior 
chamber after topical administration [46]. 
Squaramides and acyclic polyamines were selected, placing emphasis on the 
molecular properties that determine drugability but also on the commercial 
availability and affordability of the starting reagents and the production process. 
These factors are coupled with a short synthesis and simple purification steps as 
well as low cost. 
In conclusion, some of the squaramides and acyclic polyamines tested exert 
effective amoebicidal and/or cysticidal activity against A. castellanii Neff in vitro, 
comparable to control drug with less cytotoxicity, especially squaramide 3 with 
IC50 of 3.5 µM against trophozoites and cysticidal activity at concentrations of 
100 and 200 µM. Further chemical modifications and in vitro as well as in vivo 
studies are needed to understand the molecular mechanisms of action and the 
alterations produced in the amoebas, as well as to assess their ocular toxicity in 
animal models.  
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